US5045553A
(en)
*
|
1987-06-24 |
1991-09-03 |
Fujisawa Pharmaceutical Company, Ltd. |
Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
|
US4941457A
(en)
*
|
1989-08-17 |
1990-07-17 |
Olympus Optical Co., Ltd. |
Endoscope using an optical guide twisted on the tip side to have the visual field direction and curvature axis coincide with each other
|
IT1243745B
(it)
*
|
1990-10-17 |
1994-06-21 |
Vectorpharma Int |
Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
|
US5326566A
(en)
*
|
1991-05-17 |
1994-07-05 |
Bristol-Myers Squibb Company |
Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
|
US5985316A
(en)
*
|
1995-04-28 |
1999-11-16 |
Alza Corporation |
Composition and method of enhancing electrotransport agent delivery
|
US5990179A
(en)
*
|
1995-04-28 |
1999-11-23 |
Alza Corporation |
Composition and method of enhancing electrotransport agent delivery
|
US6897305B2
(en)
|
1998-06-08 |
2005-05-24 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6420354B1
(en)
|
1998-06-08 |
2002-07-16 |
Advanced Medicine, Inc. |
Sodium channel drugs and uses
|
US7101909B2
(en)
*
|
1998-10-12 |
2006-09-05 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6479498B1
(en)
|
1999-06-04 |
2002-11-12 |
Theravance, Inc. |
Sodium channel drugs and uses
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
US6214807B1
(en)
*
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
USRE47351E1
(en)
|
1999-06-22 |
2019-04-16 |
Gilead Sciences, Inc. |
2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
|
BR0108452A
(pt)
|
2000-02-18 |
2003-04-01 |
Cv Therapeutics Inc |
Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
|
AU2001238665A1
(en)
|
2000-02-23 |
2001-09-03 |
Cv Therapeutics, Inc. |
Method of identifying partial agonists of the a2a receptor
|
US7449454B2
(en)
*
|
2000-08-30 |
2008-11-11 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
US6638924B2
(en)
|
2000-08-30 |
2003-10-28 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
CA2429411A1
(en)
*
|
2000-11-17 |
2002-05-23 |
Pharmacyclics, Inc. |
Texaphyrin coordination compounds and uses thereof
|
CN1486302A
(zh)
|
2000-12-07 |
2004-03-31 |
CV���ƹ�˾ |
作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
|
US7713946B2
(en)
*
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
US7157440B2
(en)
*
|
2001-07-13 |
2007-01-02 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
NZ532816A
(en)
|
2001-11-09 |
2005-11-25 |
Cv Therapeutics Inc |
A2B adenosine receptor antagonists
|
CN101392012A
(zh)
*
|
2002-02-19 |
2009-03-25 |
Cv医药有限公司 |
A1腺苷受体的部分和全促效药
|
US20030220344A1
(en)
|
2002-04-04 |
2003-11-27 |
Luiz Belardinelli |
Method of treating arrhythmias
|
EP2332540A1
(en)
|
2002-05-21 |
2011-06-15 |
Cv Therapeutics, Inc. |
Administration of ranolazine for the treatment of diabetes
|
US8822473B2
(en)
*
|
2002-05-21 |
2014-09-02 |
Gilead Sciences, Inc. |
Method of treating diabetes
|
US20050020915A1
(en)
*
|
2002-07-29 |
2005-01-27 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging methods and compositions
|
US8470801B2
(en)
|
2002-07-29 |
2013-06-25 |
Gilead Sciences, Inc. |
Myocardial perfusion imaging methods and compositions
|
MXPA05001123A
(es)
*
|
2002-07-29 |
2005-04-29 |
Cv Therapeutics Inc |
Formacion de imagenes por perfusion de miocardio mediante el uso de agonistas receptores de a2a.
|
EP1583751A1
(en)
|
2003-01-17 |
2005-10-12 |
Cv Therapeutics, Inc. |
Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
|
US7732467B2
(en)
*
|
2003-05-15 |
2010-06-08 |
Alzheimer's Institute Of America, Inc. |
Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
|
US7314938B2
(en)
|
2003-11-05 |
2008-01-01 |
Sunesis Pharmaceuticals, Inc. |
Modulators of cellular adhesion
|
JP5254616B2
(ja)
|
2004-09-13 |
2013-08-07 |
クロノ セラピューティクス、インコーポレイテッド |
生物学的同調性(biosynchronous)経皮的薬物送達
|
EP2311462A1
(en)
|
2004-10-15 |
2011-04-20 |
Cv Therapeutics, Inc. |
Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
|
CN101076343A
(zh)
*
|
2004-10-20 |
2007-11-21 |
Cv医药有限公司 |
A2a腺苷受体激动剂的应用
|
BRPI0518322A2
(pt)
*
|
2004-11-16 |
2008-11-18 |
Limerick Neurosciences Inc |
composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
JP2006224318A
(ja)
*
|
2005-02-15 |
2006-08-31 |
Brother Ind Ltd |
インクジェット記録装置
|
US7670849B2
(en)
*
|
2005-04-29 |
2010-03-02 |
Henkin Robert I |
Method for diagnosing insulin resistance from nasal secretions
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
PT1881823E
(pt)
|
2005-05-17 |
2015-03-02 |
Sarcode Bioscience Inc |
Composições e métodos para o tratamento de transtornos oculares
|
CA2612344A1
(en)
*
|
2005-06-16 |
2006-12-28 |
Cv Therapeutics, Inc. |
Prodrugs of a2b adenosine receptor antagonists
|
EP1907395A1
(en)
|
2005-06-28 |
2008-04-09 |
Cv Therapeutics, Inc. |
Abca1 elevating compounds
|
US20070072838A1
(en)
|
2005-09-26 |
2007-03-29 |
Pharmacyclics, Inc. |
High-purity texaphyrin metal complexes
|
US20070078119A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Pharmacyclics, Inc. |
Storage system for texaphyrin pharmaceutical formulations
|
KR20080090491A
(ko)
|
2006-02-03 |
2008-10-08 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
A2a-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
|
CA2644996A1
(en)
*
|
2006-03-02 |
2007-09-13 |
Cv Therapeutics, Inc. |
A2a adenosine receptor antagonists
|
US20070219174A1
(en)
*
|
2006-03-15 |
2007-09-20 |
Pharmacyclics, Inc. |
Methods of treating cancer using hypofractionated radiation and texaphyrins
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
EP2068850A1
(en)
*
|
2006-06-22 |
2009-06-17 |
Cv Therapeutics, Inc. |
Use of a2a adenosine receptor agonists in the treatment of ischemia
|
EP2046769A2
(en)
|
2006-07-27 |
2009-04-15 |
Cv Therapeutics, Inc. |
Aldh-2 inhibitors in the treatment of addiction
|
US20080213165A1
(en)
*
|
2006-09-01 |
2008-09-04 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
|
US20090081120A1
(en)
*
|
2006-09-01 |
2009-03-26 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
|
CA2663361A1
(en)
*
|
2006-09-29 |
2008-04-10 |
Cv Therapeutics, Inc. |
Methods for myocardial imaging in patients having a history of pulmonary disease
|
US7893066B2
(en)
*
|
2006-10-05 |
2011-02-22 |
Gilead Palo Alto, Inc. |
Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
|
EP2066665A2
(en)
*
|
2006-10-05 |
2009-06-10 |
Cv Therapeutics, Inc. |
Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
|
MX2009007071A
(es)
*
|
2007-01-03 |
2009-10-13 |
Cv Therapeutics Inc |
Elaboracion de imagen de perfusion del miocardio.
|
US8293489B2
(en)
*
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
GB2448224B
(en)
|
2007-04-02 |
2010-09-01 |
Parkinson S Inst |
Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
|
WO2008123891A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Cv Therapeutics, Inc. |
PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20080255161A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20090105283A1
(en)
*
|
2007-04-11 |
2009-04-23 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
GB2463833B
(en)
*
|
2007-06-26 |
2012-02-08 |
Parkinson S Inst |
Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
|
US20090012103A1
(en)
*
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
BRPI0817516A2
(pt)
*
|
2007-10-05 |
2015-06-16 |
Alzheimer S Inst Of America Inc |
Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino
|
US20100093810A1
(en)
*
|
2007-10-05 |
2010-04-15 |
Alzheimer's Institute Of America, Inc. |
Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
|
EP3797775A1
(en)
|
2007-10-19 |
2021-03-31 |
Novartis AG |
Compositions and methods for treatment of diabetic retinopathy
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2240452B1
(en)
|
2008-01-04 |
2019-05-29 |
Intellikine, LLC |
1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as pi3 kinase modulators, their compositions and uses
|
JP2011511802A
(ja)
*
|
2008-02-07 |
2011-04-14 |
ギリアード・パロ・アルト・インコーポレイテッド |
Abca−1を上昇させる化合物およびかかる化合物の使用方法
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
KR20100132999A
(ko)
*
|
2008-04-04 |
2010-12-20 |
길리애드 사이언시즈, 인코포레이티드 |
스테아로일 CoA 불포화 효소 억제제로서 사용하기 위한 트리아졸로피리디논 유도체
|
CN102065893A
(zh)
*
|
2008-04-15 |
2011-05-18 |
萨可德公司 |
Lfa-1拮抗剂向胃肠系统的递送
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
EP2265124A4
(en)
*
|
2008-04-15 |
2011-12-28 |
Sarcode Bioscience Inc |
AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
|
EP3632444A3
(en)
*
|
2008-04-15 |
2020-08-26 |
SARcode Bioscience Inc. |
Topical lfa-1 antagonists for use in localized treatment of immune related disorders
|
NZ590258A
(en)
|
2008-07-08 |
2013-10-25 |
Intellikine Llc |
Kinase inhibitors and methods of use
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
US8580801B2
(en)
*
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
KR20110063556A
(ko)
*
|
2008-09-29 |
2011-06-10 |
길리애드 사이언시즈, 인코포레이티드 |
다검출 전산화 단층 촬영법에 사용하기 위한 a-2-알파 수용체 길항제와 속도 조절제의 조합물
|
CN102216257B
(zh)
|
2008-10-08 |
2015-11-25 |
凯飞药业公司 |
Gaba偶联物及其使用方法
|
US10098857B2
(en)
|
2008-10-10 |
2018-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
|
WO2010045374A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Gilead Palo Alto, Inc. |
3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
|
WO2010074807A1
(en)
|
2008-10-30 |
2010-07-01 |
Gilead Palo Alto, Inc. |
3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
|
US8389500B2
(en)
|
2008-10-30 |
2013-03-05 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
US20100120727A1
(en)
*
|
2008-11-12 |
2010-05-13 |
Kyphia Pharmaceuticals, Inc. |
Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
EP2429526A1
(en)
*
|
2009-05-14 |
2012-03-21 |
Gilead Sciences, Inc. |
Ranolazine for the treatment of cns disorders
|
WO2010144611A2
(en)
*
|
2009-06-10 |
2010-12-16 |
3-V Biosciences, Inc. |
Antivirals that target transporters, carriers, and ion channels
|
TWI491606B
(zh)
|
2009-07-13 |
2015-07-11 |
Gilead Sciences Inc |
調節細胞凋亡信號之激酶的抑制劑
|
DK2464645T3
(en)
*
|
2009-07-27 |
2017-10-23 |
Gilead Sciences Inc |
CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
|
US20110039799A1
(en)
|
2009-08-14 |
2011-02-17 |
Gilead Palo Alto, Inc. |
A1 adenosine receptor agonist polymorphs
|
CN105078978A
(zh)
|
2009-08-17 |
2015-11-25 |
因特利凯公司 |
杂环化合物及其用途
|
US8378105B2
(en)
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
WO2011056985A2
(en)
|
2009-11-04 |
2011-05-12 |
Gilead Sciences, Inc. |
Substituted heterocyclic compounds
|
US9562056B2
(en)
|
2010-03-11 |
2017-02-07 |
Gilead Connecticut, Inc. |
Imidazopyridines Syk inhibitors
|
CN103002738A
(zh)
|
2010-05-21 |
2013-03-27 |
英特利凯恩有限责任公司 |
用于激酶调节的化学化合物、组合物和方法
|
EP2595630A1
(en)
|
2010-06-30 |
2013-05-29 |
Gilead Sciences, Inc. |
Use of a2b adenosine receptor antagonists for treating pulmonary hypertension
|
BR112012033402A2
(pt)
|
2010-07-02 |
2017-01-24 |
Gilead Sciences Inc |
moduladores de canais de íons conforme os compostos heterocíclicos fundidos
|
EA023040B1
(ru)
|
2010-07-02 |
2016-04-29 |
Джилид Сайэнс, Инк. |
Ингибиторы киназ, регулирующих апоптозный сигнал
|
WO2012018387A2
(en)
|
2010-08-02 |
2012-02-09 |
Population Diagnotics, Inc. |
Compositions and methods for discovery of causative mutations in genetic disorders
|
US8901133B2
(en)
|
2010-11-10 |
2014-12-02 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6378878B2
(ja)
|
2011-01-07 |
2018-08-22 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
メラニン改変組成物および使用方法
|
EP2663309B1
(en)
|
2011-01-10 |
2017-03-15 |
Infinity Pharmaceuticals, Inc. |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
CN105001225B
(zh)
|
2011-03-08 |
2018-04-06 |
3-V 生物科学公司 |
脂质合成的杂环调节剂
|
AR085942A1
(es)
|
2011-04-07 |
2013-11-06 |
Gilead Sciences Inc |
Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
|
US9115096B2
(en)
|
2011-05-10 |
2015-08-25 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
UY34171A
(es)
|
2011-07-01 |
2013-01-31 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como moduladores del canal iónico
|
NO3175985T3
(pt)
|
2011-07-01 |
2018-04-28 |
|
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013012918A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
AR087700A1
(es)
|
2011-08-30 |
2014-04-09 |
Gilead Sciences Inc |
Inhibidores de aldh-2 en el tratamiento de adicciones
|
US20140221286A1
(en)
|
2011-09-21 |
2014-08-07 |
Gilead Sciences, Inc. |
Sodium channel blockers reduce glucagon secretion
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US10221454B2
(en)
|
2011-10-10 |
2019-03-05 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
EP2773779B1
(en)
|
2011-11-04 |
2020-10-14 |
Population Bio, Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
DK2812452T3
(da)
|
2012-02-09 |
2020-06-29 |
Population Bio Inc |
Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
|
EP2817004B1
(en)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8969588B2
(en)
|
2012-06-05 |
2015-03-03 |
Gilead Pharmasset Llc |
Solid forms of an antiviral compound
|
US9321749B1
(en)
|
2012-07-25 |
2016-04-26 |
Globavir Biosciences, Inc. |
Heterocyclic compounds and uses thereof
|
MX2015001098A
(es)
|
2012-07-25 |
2015-09-25 |
Sarcode Bioscience Inc |
Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
EP2895621B1
(en)
|
2012-09-14 |
2020-10-21 |
Population Bio, Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
EP2900835A4
(en)
|
2012-09-27 |
2016-05-11 |
Population Diagnotics Inc |
METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS
|
US20140120060A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
|
JP6584952B2
(ja)
|
2012-11-01 |
2019-10-02 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
Pi3キナーゼアイソフォームモジュレーターを用いる癌の治療
|
UY35212A
(es)
|
2012-12-21 |
2014-06-30 |
Gilead Sciences Inc |
Inhibidores de la quinasa que regula la señal de la apoptosis
|
PT2941426T
(pt)
|
2012-12-21 |
2018-07-18 |
Gilead Calistoga Llc |
Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase
|
US9029384B2
(en)
|
2012-12-21 |
2015-05-12 |
Gilead Calistoga, LLC. |
Phosphatidylinositol 3-kinase inhibitors
|
JP6154025B2
(ja)
|
2012-12-24 |
2017-06-28 |
ニューロガストルクス,インコーポレイテッド |
Gi管障害を治療するための方法
|
CA2906542A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
US20160024051A1
(en)
|
2013-03-15 |
2016-01-28 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
TWI530499B
(zh)
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
EP3811974A1
(en)
|
2013-05-30 |
2021-04-28 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
NZ714710A
(en)
|
2013-06-14 |
2016-11-25 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
NZ715747A
(en)
|
2013-07-31 |
2017-03-31 |
Gilead Sciences Inc |
Syk inhibitors
|
HUE036600T2
(hu)
|
2013-10-03 |
2018-07-30 |
Kura Oncology Inc |
ERK inhibitorok és alkalmazási eljárások
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MX2016004340A
(es)
|
2013-10-04 |
2016-08-08 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6262363B2
(ja)
|
2013-11-26 |
2018-01-17 |
ギリアード サイエンシーズ, インコーポレイテッド |
ブロモドメイン阻害剤としてのキノリン誘導体
|
EA201690608A1
(ru)
|
2013-12-04 |
2016-12-30 |
Джилид Сайэнс, Инк. |
Способы лечения раковых заболеваний
|
EA201691169A1
(ru)
|
2013-12-05 |
2016-09-30 |
Асерта Фарма Б.В. |
Терапевтическая комбинация ингибитора pi3k и ингибитора btk
|
US9416128B2
(en)
|
2013-12-19 |
2016-08-16 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
JP6568541B2
(ja)
|
2013-12-23 |
2019-08-28 |
ギリアド ファーマセット エルエルシー |
大環状hcv ns3阻害トリペプチドの結晶形態
|
TWI662037B
(zh)
|
2013-12-23 |
2019-06-11 |
美商基利科學股份有限公司 |
脾酪胺酸激酶抑制劑
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
TW201613908A
(en)
|
2014-02-13 |
2016-04-16 |
Gilead Sciences Inc |
Solid forms of an ion channel modulator
|
EP3108245B1
(en)
|
2014-02-18 |
2020-07-22 |
Robert I. Henkin |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
WO2015181633A2
(en)
|
2014-04-11 |
2015-12-03 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
WO2015185998A2
(en)
|
2014-04-11 |
2015-12-10 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
US10040767B2
(en)
|
2014-05-15 |
2018-08-07 |
Peloton Therapeutics, Inc. |
Benzimidazole derivatives and uses thereof
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
KR20170012558A
(ko)
|
2014-06-13 |
2017-02-02 |
길리애드 사이언시즈, 인코포레이티드 |
포스파티딜이노시톨 3-키나제 억제제
|
US11021467B2
(en)
|
2014-06-13 |
2021-06-01 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
US10227342B2
(en)
|
2014-06-19 |
2019-03-12 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
WO2015200369A1
(en)
|
2014-06-24 |
2015-12-30 |
Neurogastrx, Inc. |
Prodrugs of metopimazine
|
US9707236B2
(en)
|
2014-07-14 |
2017-07-18 |
Gilead Sciences, Inc. |
Combination methods for treating cancers
|
EP3169699A4
(en)
|
2014-07-18 |
2018-06-20 |
The University of Washington |
Cancer vaccine compositions and methods of use thereof
|
WO2016024227A1
(en)
|
2014-08-11 |
2016-02-18 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
WO2016036403A1
(en)
|
2014-09-05 |
2016-03-10 |
Population Diagnostics Inc. |
Methods and compositions for inhibiting and treating neurological conditions
|
KR101949624B1
(ko)
|
2014-09-26 |
2019-02-18 |
길리애드 사이언시즈, 인코포레이티드 |
Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
CN111825717A
(zh)
|
2014-10-21 |
2020-10-27 |
阿瑞雅德制药公司 |
5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
MA41252A
(fr)
|
2014-12-23 |
2017-10-31 |
Gilead Sciences Inc |
Formes solides d'un inhibiteur d'ask 1
|
DK3251699T3
(da)
|
2015-01-28 |
2024-05-21 |
Univ Duke |
Sammensætning omfattende methylphenidat og ondansetron til anvendelse i stofrelaterede forstyrrelser
|
WO2016123406A1
(en)
|
2015-01-28 |
2016-08-04 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
US10155726B2
(en)
|
2015-03-11 |
2018-12-18 |
Peloton Therapeutics, Inc. |
Substituted pyridines and uses thereof
|
US10278942B2
(en)
|
2015-03-11 |
2019-05-07 |
Peloton Therapeutics, Inc. |
Compositions for use in treating pulmonary arterial hypertension
|
ES2910049T3
(es)
|
2015-03-19 |
2022-05-11 |
Sagimet Biosciences Inc |
Moduladores heterocíclicos de la síntesis de lípidos
|
PL3191470T3
(pl)
|
2015-07-06 |
2019-08-30 |
Gilead Sciences, Inc. |
Modulatory Cot i sposoby ich zastosowania
|
US10858316B2
(en)
|
2015-07-10 |
2020-12-08 |
University Of Maryland, Baltimore |
Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
CA3005212C
(en)
|
2015-11-11 |
2024-01-23 |
Warner Babcock Institute for Green Chemistry |
Benzofuran derivatives for the treatment of cns and other disorders
|
CA3006772A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Tank-binding kinase inhibitor compounds
|
WO2017122175A1
(en)
|
2016-01-13 |
2017-07-20 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
US20190119236A1
(en)
|
2016-02-23 |
2019-04-25 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
JP2019510752A
(ja)
|
2016-03-04 |
2019-04-18 |
ギリアード サイエンシーズ, インコーポレイテッド |
オートタキシン阻害剤の組成物及び合剤
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2017218802A1
(en)
|
2016-06-15 |
2017-12-21 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
EP3474835B1
(en)
|
2016-06-23 |
2023-07-05 |
University of Maryland, Baltimore |
Non-catalytic substrate-selective p38 -specific mapk inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
|
JP6776378B2
(ja)
|
2016-06-30 |
2020-10-28 |
ギリアード サイエンシーズ, インコーポレイテッド |
Cotモジュレーターとしての4,6−ジアミノキナゾリン類およびその使用方法
|
US10111882B2
(en)
|
2016-09-14 |
2018-10-30 |
Gilead Sciences, Inc. |
SYK inhibitors
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
WO2018075601A1
(en)
|
2016-10-18 |
2018-04-26 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018085833A2
(en)
|
2016-11-07 |
2018-05-11 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
|
WO2018085818A1
(en)
|
2016-11-07 |
2018-05-11 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
US11261188B2
(en)
|
2016-11-28 |
2022-03-01 |
Praxis Precision Medicines, Inc. |
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
|
EP3548033B1
(en)
|
2016-11-28 |
2024-04-10 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
AR110252A1
(es)
|
2016-11-30 |
2019-03-13 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
|
WO2018129304A1
(en)
|
2017-01-06 |
2018-07-12 |
Chrono Therapeutics Inc. |
Transdermal drug delivery devices and methods
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
JOP20180009A1
(ar)
|
2017-02-06 |
2019-01-30 |
Gilead Sciences Inc |
مركبات مثبط فيروس hiv
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
WO2018152501A1
(en)
|
2017-02-20 |
2018-08-23 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018152548A1
(en)
|
2017-02-20 |
2018-08-23 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018160855A1
(en)
|
2017-03-01 |
2018-09-07 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
WO2018160824A1
(en)
|
2017-03-01 |
2018-09-07 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
EP3601326A4
(en)
|
2017-03-20 |
2020-12-16 |
The Broad Institute, Inc. |
COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
|
US11731966B2
(en)
|
2017-04-04 |
2023-08-22 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
WO2018195471A1
(en)
|
2017-04-21 |
2018-10-25 |
Gilead Sciences, Inc. |
Syk inhibitors in combination with hypomethylating agents
|
WO2018208709A1
(en)
|
2017-05-09 |
2018-11-15 |
Warner Babcock Institute For Green Chemistry, Llc |
Stilbene derivatives for the treatment of cns and other disorders
|
EP3641741B1
(en)
|
2017-06-19 |
2024-03-20 |
University of Maryland, Baltimore |
Microtubule polymerization inhibitor prodrugs and methods of using the same
|
ES2885180T3
(es)
|
2017-08-09 |
2021-12-13 |
Prelude Therapeutics Inc |
Inhibidores selectivos de la proteína arginina metiltransferasa 5 (PRMT5)
|
WO2019035951A1
(en)
|
2017-08-15 |
2019-02-21 |
Praxis Precision Medicines, Inc. |
COMPOUNDS AND THEIR METHODS OF USE
|
TW202024061A
(zh)
|
2017-08-17 |
2020-07-01 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
KR20200043439A
(ko)
|
2017-08-22 |
2020-04-27 |
길리애드 사이언시즈, 인코포레이티드 |
치료 헤테로시클릭 화합물
|
WO2019055490A1
(en)
|
2017-09-14 |
2019-03-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
|
CN117417281A
(zh)
|
2017-09-28 |
2024-01-19 |
麦迪康制药公司 |
抗炎、抗癌和抗血管生成化合物,药物组合物及其制备和使用方法
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
CN111542525B
(zh)
|
2017-10-26 |
2023-06-27 |
普莱鲁德疗法有限公司 |
蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
|
EP3710599B1
(en)
|
2017-11-13 |
2024-07-17 |
Gilead Sciences, Inc. |
Method for staging liver fibrosis in nash patients
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
JP7083398B2
(ja)
|
2018-02-15 |
2022-06-10 |
ギリアード サイエンシーズ, インコーポレイテッド |
ピリジン誘導体およびhiv感染を処置するためのその使用
|
PL3752496T3
(pl)
|
2018-02-16 |
2023-11-27 |
Gilead Sciences, Inc. |
Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae
|
EP3758494A4
(en)
|
2018-03-02 |
2022-03-16 |
Oregon Health & Science University |
AMIDPRODRUGS OF SMALL MOLECULES NUCLEAR RECEPTOR MODULATORS
|
PL3765461T3
(pl)
|
2018-03-14 |
2024-03-04 |
Prelude Therapeutics, Incorporated |
Selektywne inhibitory białkowej metylotranserazy argininy 5 (prmt5)
|
US10711007B2
(en)
|
2018-03-14 |
2020-07-14 |
Prelude Therapeutics Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
|
WO2019196622A1
(zh)
|
2018-04-09 |
2019-10-17 |
威尚(上海)生物医药有限公司 |
具有穿过血脑屏障能力的5取代二氟哌啶化合物
|
JP7441181B2
(ja)
|
2018-05-14 |
2024-02-29 |
エックスジーン ファーマシューティカル インク. |
ナプロキセンとプレガバリンの1-(アシルオキシ)-アルキルカルバメート薬品複合体の結晶形態
|
JP7420797B2
(ja)
|
2018-05-29 |
2024-01-23 |
モーニングサイド ベンチャー インベストメンツ リミテッド |
薬剤送達の方法及びシステム
|
US11866439B2
(en)
|
2018-05-30 |
2024-01-09 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
CN112384505A
(zh)
|
2018-07-06 |
2021-02-19 |
吉利德科学公司 |
治疗性的杂环化合物
|
JP7199502B2
(ja)
|
2018-07-06 |
2023-01-05 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用複素環式化合物
|
TWI814350B
(zh)
|
2018-07-16 |
2023-09-01 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
FI3625368T3
(fi)
|
2018-08-08 |
2023-01-13 |
|
Menetelmiä john cunningham -viruksen aiheuttaman progressiivin multifokaalin leukoenkefalopatian kehittymisen riskin arviointiin geneettisellä testauksella
|
AU2019329835A1
(en)
|
2018-08-27 |
2021-04-15 |
Spinogenix, Inc. |
Fascin binding compounds for spinogenesis
|
ES2966707T3
(es)
|
2018-10-01 |
2024-04-23 |
Global Blood Therapeutics Inc |
Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
TW202136261A
(zh)
|
2018-10-31 |
2021-10-01 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
DK3873903T3
(da)
|
2018-10-31 |
2024-04-02 |
Gilead Sciences Inc |
Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
|
KR20210089662A
(ko)
|
2018-11-09 |
2021-07-16 |
프렐루드 테라퓨틱스, 인코포레이티드 |
골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서 스피로-술폰아미드 유도체
|
CN113316568A
(zh)
|
2018-11-19 |
2021-08-27 |
全球血液疗法股份有限公司 |
能够调节血红蛋白的2-甲酰基-3-羟基苯基氧基甲基化合物
|
WO2020118194A1
(en)
|
2018-12-07 |
2020-06-11 |
University Of Maryland, Baltimore |
NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
|
WO2020123861A1
(en)
|
2018-12-12 |
2020-06-18 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
EP3894416B1
(en)
|
2018-12-13 |
2022-11-09 |
Global Blood Therapeutics, Inc. |
Ferroportin inhibitors and methods of use
|
US20220064170A1
(en)
|
2018-12-14 |
2022-03-03 |
Prelude Therapeutics, Incorporated |
Bicyclic heterocyclic derivatives and their use as pharmaceuticals
|
WO2020163637A1
(en)
|
2019-02-06 |
2020-08-13 |
Oregon Health & Science University |
Bisphosphonate-linked compounds
|
CN113811539A
(zh)
|
2019-02-13 |
2021-12-17 |
普莱鲁德疗法有限公司 |
蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
|
KR20210131372A
(ko)
|
2019-02-22 |
2021-11-02 |
크로노스 바이오, 인코포레이티드 |
Syk 억제제로서의 축합된 피라진의 고체 형태
|
WO2020176424A1
(en)
|
2019-02-25 |
2020-09-03 |
Chdi Foundation, Inc. |
Compounds for targeting mutant huntingtin protein and uses thereof
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
US11667606B2
(en)
|
2019-03-01 |
2023-06-06 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
MX2021013421A
(es)
|
2019-05-03 |
2022-02-11 |
Praxis Prec Medicines Inc |
Inhibidores de kcnt1 y metodos de uso.
|
US11773099B2
(en)
|
2019-05-28 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11279700B2
(en)
|
2019-05-31 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
US11505554B2
(en)
|
2019-05-31 |
2022-11-22 |
Praxis Precision Medicines, Inc. |
Substituted pyridines as ion channel modulators
|
TW202235416A
(zh)
|
2019-06-14 |
2022-09-16 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
BR112022000429A2
(pt)
|
2019-07-11 |
2022-03-29 |
Praxis Prec Medicines Inc |
Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos
|
WO2021055797A1
(en)
|
2019-09-18 |
2021-03-25 |
Prelude Therapeutics, Incorporated |
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
|
CN114787144A
(zh)
|
2019-09-26 |
2022-07-22 |
埃克塞里艾克西斯公司 |
吡啶酮化合物及用于调节蛋白激酶的方法
|
WO2021108544A1
(en)
|
2019-11-26 |
2021-06-03 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
CA3163091A1
(en)
|
2019-11-27 |
2021-06-03 |
Praxis Precision Medicines, Inc. |
Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
|
WO2021155253A1
(en)
|
2020-01-31 |
2021-08-05 |
Atomwise Inc. |
Anat inhibitors and methods of use thereof
|
EP4110783A1
(en)
|
2020-02-24 |
2023-01-04 |
Gilead Sciences, Inc. |
Tetracyclic compounds for treating hiv infection
|
JP2023514725A
(ja)
|
2020-02-24 |
2023-04-07 |
エグゼリクシス, インコーポレイテッド |
化合物および使用方法
|
CN115443129A
(zh)
|
2020-02-28 |
2022-12-06 |
普拉西斯精密医药公司 |
Kcnt1抑制剂和使用方法
|
US11655237B2
(en)
|
2020-03-30 |
2023-05-23 |
Gilead Sciences, Inc. |
Solid forms of a Cot inhibitor compound
|
BR112022019423A2
(pt)
|
2020-03-31 |
2022-12-06 |
Global Blood Therapeutics Inc |
Moduladores de hemoglobina
|
WO2021202796A1
(en)
|
2020-04-01 |
2021-10-07 |
Global Blood Therapeutics, Inc. |
Pyrrolidine-pyrazoles as pyruvate kinase activators
|
EP4126862A1
(en)
|
2020-04-02 |
2023-02-08 |
Gilead Sciences, Inc. |
Process for preparing a cot inhibitor compound
|
US10836757B1
(en)
|
2020-04-02 |
2020-11-17 |
Neurogastrx, Inc. |
Polymorphic forms of metopimazine
|
WO2021211922A1
(en)
|
2020-04-16 |
2021-10-21 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
EP4143197A1
(en)
|
2020-04-28 |
2023-03-08 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
BR112022021806A2
(pt)
|
2020-04-28 |
2022-12-13 |
Global Blood Therapeutics Inc |
Cicloalquilpirimidinas como inibidores de ferroportina
|
EP4142732A1
(en)
|
2020-04-28 |
2023-03-08 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
KR20230024287A
(ko)
|
2020-05-13 |
2023-02-20 |
프렐루드 테라퓨틱스, 인코포레이티드 |
골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서의 스피로-술폰아미드 유도체
|
US11702423B2
(en)
|
2020-06-09 |
2023-07-18 |
Prelude Therapeutics Incorporated |
BRM targeting compounds and associated methods of use
|
US11680064B2
(en)
|
2020-06-25 |
2023-06-20 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of HIV
|
WO2022031735A1
(en)
|
2020-08-03 |
2022-02-10 |
Global Blood Therapeutics, Inc. |
Urea derivatives as pyruvate kinase activators
|
CN116096378A
(zh)
|
2020-08-10 |
2023-05-09 |
诺华股份有限公司 |
视网膜变性疾病的治疗
|
WO2022061273A1
(en)
|
2020-09-21 |
2022-03-24 |
Prelude Therapeutics, Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
CA3192145A1
(en)
|
2020-09-30 |
2022-04-07 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
WO2022069701A1
(en)
|
2020-10-01 |
2022-04-07 |
Nogra Pharma Limited |
Methods of treating pulmonary fibrosis
|
US11773088B2
(en)
|
2020-11-02 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
KCNT1 inhibitors and methods of use
|
CA3200685A1
(en)
|
2020-11-06 |
2022-05-12 |
Prelude Therapeutics Incorporated |
Brm targeting compounds and associated methods of use
|
IL303779A
(en)
|
2020-12-18 |
2023-08-01 |
Prelude Therapeutics Inc |
CDK inhibitors and their use as drugs
|
US20240059673A1
(en)
|
2020-12-22 |
2024-02-22 |
Gilead Sciences, Inc. |
Substituted indole compounds
|
EP4267560A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
6-substituted indole compounds
|
EP4267585A1
(en)
|
2020-12-23 |
2023-11-01 |
Actelion Pharmaceuticals Ltd |
Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
|
CA3205986A1
(en)
|
2020-12-30 |
2022-07-07 |
Tyra Biosciences, Inc. |
Indazole compounds as kinase inhibitors
|
HRP20231654T1
(hr)
|
2021-01-19 |
2024-03-15 |
Gilead Sciences, Inc. |
Supstituirani spojevi piridotriazina i njihove uporabe
|
TW202245758A
(zh)
|
2021-02-08 |
2022-12-01 |
美商全球血液治療公司 |
作為丙酮酸激酶活化劑之吡咯啶-吡唑
|
WO2022173722A1
(en)
|
2021-02-09 |
2022-08-18 |
Gilead Sciences, Inc. |
Thienopyrrole compounds
|
CA3211063A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
BR112023021107A2
(pt)
|
2021-04-16 |
2023-12-12 |
Gilead Sciences Inc |
Compostos de tienopirrol
|
TW202311254A
(zh)
|
2021-05-14 |
2023-03-16 |
美商全球血液治療公司 |
血紅素之調節劑之固態形式
|
TW202345826A
(zh)
|
2021-06-04 |
2023-12-01 |
美商基利科學股份有限公司 |
治療nash之方法
|
WO2022266370A1
(en)
|
2021-06-17 |
2022-12-22 |
Aria Pharmaceuticals, Inc. |
Sparsentan for treating idiopathic pulmonary fibrosis
|
TW202311256A
(zh)
|
2021-06-18 |
2023-03-16 |
美商基利科學股份有限公司 |
用於治療fxr誘發之搔癢之il-31調節劑
|
WO2023279041A1
(en)
|
2021-06-30 |
2023-01-05 |
Tyra Biosciences, Inc. |
Indazole compounds
|
TW202317533A
(zh)
|
2021-07-02 |
2023-05-01 |
美商雅斯治療公司 |
奧沙奈坦(osanetant)之固體形式
|
WO2023287787A1
(en)
|
2021-07-13 |
2023-01-19 |
Prelude Therapeutics, Incorporated |
Brm targeting compounds and associated methods of use
|
TW202313053A
(zh)
|
2021-07-30 |
2023-04-01 |
瑞士商艾克泰聯製藥有限公司 |
吡唑并嘧啶及其作為pdgfr抑制劑之用途
|
WO2023034530A1
(en)
|
2021-09-02 |
2023-03-09 |
Teon Therapeutics, Inc. |
Methods of improving growth and function of immune cells
|
US12070455B2
(en)
|
2021-09-10 |
2024-08-27 |
Gilead Sciences, Inc. |
Thienopyrrole compounds
|
US20230144528A1
(en)
|
2021-09-30 |
2023-05-11 |
Prelude Therapeutics Incorporated |
CDK Inhibitors And Their Use As Pharmaceuticals
|
WO2023060134A1
(en)
|
2021-10-06 |
2023-04-13 |
Global Blood Therapeutics, Inc. |
Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
|
WO2023076404A1
(en)
|
2021-10-27 |
2023-05-04 |
Aria Pharmaceuticals, Inc. |
Methods for treating systemic lupus erythematosus
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
WO2023097234A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097233A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097230A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
MX2024006396A
(es)
|
2021-12-03 |
2024-06-04 |
Gilead Sciences Inc |
Compuestos terapeuticos para la infeccion por el virus de inmunodeficiencia humana (vih).
|
AU2022399845A1
(en)
|
2021-12-03 |
2024-05-23 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
KR20240113832A
(ko)
|
2021-12-03 |
2024-07-23 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 바이러스 감염 치료용 화합물
|
CA3241881A1
(en)
|
2021-12-10 |
2023-06-15 |
Global Blood Therapeutics, Inc. |
Methods of administering a modulator of hemoglobin
|
WO2023141571A1
(en)
|
2022-01-21 |
2023-07-27 |
Prelude Therapeutics, Incorporated |
Cdk inhibitors and their use as pharmaceuticals
|
WO2023147312A1
(en)
|
2022-01-25 |
2023-08-03 |
Evvia Therapeutics, Inc. |
Ampk agonists and methods of use thereof
|
WO2023147135A1
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Nk receptor antagonists for treatment of prostate cancer
|
WO2023147134A2
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Methods for treating patients having low estrogen with nk3 antagonists
|
US20230257394A1
(en)
|
2022-02-03 |
2023-08-17 |
Prelude Therapeutics, Incorporated |
CDK Inhibitors And Their Use As Pharmaceuticals
|
WO2023172957A1
(en)
|
2022-03-09 |
2023-09-14 |
Prelude Therapeutics, Incorporated |
Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals
|
WO2023178547A1
(en)
|
2022-03-23 |
2023-09-28 |
Prelude Therapeutics, Incorporated |
Polymorphic compounds and uses thereof
|
WO2023192416A1
(en)
|
2022-03-29 |
2023-10-05 |
Prelude Therapeutics, Incorporated |
Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
|
WO2023192506A1
(en)
|
2022-03-31 |
2023-10-05 |
Rarified Biosciences, Inc. |
Malt1 modulators and uses thereof
|
TWI843506B
(zh)
|
2022-04-06 |
2024-05-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
WO2023215220A1
(en)
|
2022-05-02 |
2023-11-09 |
Esperion Therapeutics, Inc. |
Macrocyclic inhibitors of atp citrate lyase
|
WO2023220577A1
(en)
|
2022-05-10 |
2023-11-16 |
Prelude Therapeutics, Incorporated |
6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
|
WO2023225162A1
(en)
|
2022-05-20 |
2023-11-23 |
Gilead Sciences, Inc. |
Antiviral indolinyl compounds and uses thereof
|
US12018009B2
(en)
|
2022-06-14 |
2024-06-25 |
Amygdala Neurosciences, Inc. |
ALDH-2 inhibitor compounds and methods of use
|
WO2023244563A1
(en)
|
2022-06-14 |
2023-12-21 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
US20230416240A1
(en)
|
2022-06-16 |
2023-12-28 |
Prelude Therapeutics Incorporated |
Kat6 targeting compounds
|
WO2023247590A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
|
WO2023247595A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
|
WO2023247593A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
|
WO2023247596A1
(en)
|
2022-06-22 |
2023-12-28 |
Actelion Pharmaceuticals Ltd |
Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
|
TW202408493A
(zh)
|
2022-06-29 |
2024-03-01 |
美商泰拉生物科學公司 |
多晶形化合物及其用途
|
TW202416961A
(zh)
|
2022-06-29 |
2024-05-01 |
美商泰拉生物科學公司 |
吲唑化合物
|
WO2024015827A1
(en)
|
2022-07-12 |
2024-01-18 |
Hotspot Therapeutics, Inc. |
Solid forms of a triazine derivative as cbl-b modulator
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024015416A1
(en)
|
2022-07-15 |
2024-01-18 |
Celloram Inc. |
Celastrol derivatives
|
WO2024047394A1
(en)
|
2022-08-31 |
2024-03-07 |
Otsuka Pharmaceutical Co., Ltd. |
Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
|
US20240150340A1
(en)
|
2022-10-06 |
2024-05-09 |
Prelude Therapeutics Incorporated |
CDK Inhibitors And Their Use As Pharmaceuticals
|
WO2024089668A1
(en)
|
2022-10-28 |
2024-05-02 |
Basecamp Bio Inc. |
Somatostatin receptor 2 agonists and uses thereof
|
WO2024104968A1
(en)
|
2022-11-14 |
2024-05-23 |
Actelion Pharmaceuticals Ltd |
Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors
|
US20240190886A1
(en)
|
2022-11-15 |
2024-06-13 |
Prelude Therapeutics Incorporated |
BRM Targeting Compounds and Associated Methods of Use
|
WO2024138112A1
(en)
|
2022-12-22 |
2024-06-27 |
Tyra Biosciences, Inc. |
Indazole compounds
|